Associated Banc Corp Grows Position in Boston Scientific Corporation $BSX

Associated Banc Corp lifted its position in Boston Scientific Corporation (NYSE:BSX) by 28.5% during the 1st quarter, Holdings Channel reports. The firm owned 480,358 shares of the medical equipment provider’s stock after acquiring an additional 106,526 shares during the period. Associated Banc Corp’s holdings in Boston Scientific were worth $30,142,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BSX. Brighton Jones LLC boosted its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter worth $26,000. Main Street Financial Solutions LLC increased its position in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC raised its stake in shares of Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC raised its stake in shares of Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Bank of America cut their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Needham & Company LLC cut their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday. Raymond James Financial reissued an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Finally, Truist Financial dropped their price target on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.32.

Boston Scientific Stock Down 0.7%

Boston Scientific stock traded down $0.32 during trading hours on Friday, hitting $44.67. 12,037,584 shares of the stock traded hands, compared to its average volume of 18,748,692. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50. The firm’s 50-day moving average price is $49.41 and its two-hundred day moving average price is $67.70. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market cap of $66.40 billion, a PE ratio of 18.69, a PEG ratio of 0.86 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.